Mizuho reiterates BridgeBio stock rating ahead of Pfizer trial By Investing.com

Mizuho reiterated an Outperform rating and $106 price target on BridgeBio Pharma ahead of Pfizer’s five-day tafamidis patent trial from April 27 to May 1, saying an outright win could push the stock into the $100-$110 range or higher. The firm believes a generic tafamidis would have limited impact on Attruby sales, while the market has been modeling IP protection only through year-end 2028. Recent updates, including the BBP-418 NDA filing and multiple bullish analyst targets, reinforce a positive outlook, though the near-term stock reaction hinges on the patent case.

Analysis

The market is treating the patent trial as a binary event, but the more important setup is that BBIO’s multiple is now increasingly tied to durability of cash flows rather than current quarter execution. Even if Pfizer wins, the damage to Attruby is likely more about compressing the terminal value of the franchise and forcing the Street to haircut the post-2028 growth curve, not an immediate collapse in sales. That means the stock can re-rate sharply on any indication the patent moat is stronger than consensus, because the current valuation still appears to embed a conservative long-duration litigation discount.

The second-order winner is the broader BBIO pipeline optionality: if Attruby’s perceived moat improves, management gets more credibility on funding BBP-418 and encaleret without the market demanding punitive dilution or a lower sum-of-the-parts multiple. Conversely, a Pfizer-leaning outcome would likely not just pressure BBIO directly; it could also raise skepticism across late-stage rare-disease commercial launches where IP is the main underwriting variable. That spillover could hit peers with similar “single-asset now, pipeline later” profiles by widening the discount rate applied to future launch economics.

Catalyst timing matters: the trial itself may not resolve immediately, but the stock can move on courtroom tone, expert credibility, or any indication of settlement probabilities before a final ruling. The key tail risk is not just losing the patent case, but the market deciding that management’s confidence around franchise longevity is less reliable, which would hit multiple expansion for months. On the upside, a favorable read could force a fast repricing because this is one of the few near-term events capable of changing 2025-2028 consensus revenue assumptions in a single step.

The contrarian view is that the consensus may be underestimating how little of the current valuation actually depends on the disputed patent window. If Attruby demand is genuinely being driven by physician adoption and class positioning, the stock may prove more resilient than litigational models imply. But if the Street is right that this is a duration story, then the move from here will be less about quarterly beats and more about whether the market starts discounting a structurally shorter growth runway.

Key Decisions for Investors

• Go long BBIO into the trial window with a 1-3 week horizon; use a call spread to define downside and capture a potential re-rating if courtroom signals lean favorable. Risk/reward is attractive because the stock can gap on incremental legal cues before final judgment.
• If already long BBIO from lower levels, trim 20-30% into strength ahead of headline risk and retain upside via calls. This preserves exposure to a positive ruling while reducing gap risk from an adverse read.
• Consider a BBIO/PFE pair trade: long BBIO vs short PFE sized modestly, only as a catalyst trade. The logic is that any outcome preserving BBIO’s moat is more asymmetrically positive for BBIO than negative for PFE, but the pair should be kept small because legal outcomes are noisy.
• Avoid chasing BBIO after a large pre-trial move unless there is a pullback or improved trial signal. The event is binary enough that entry discipline matters more than conviction.
• For event-driven accounts, buy short-dated BBIO upside calls and finance with out-of-the-money puts only if implied volatility remains below the realized event-risk premium. If IV is already elevated, the cleaner expression is stock plus tight stop on post-hearing weakness.